Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 503

Sort by

Sort Order Select

Journal Articles

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Blood (2024) 144 (17): 1813–1820.

https://doi.org/10.1182/blood.2024025802

Published: 2024

Journal Articles

CALR mutation burden in essential thrombocythemia and disease outcome

Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Michaël Harnois, Omer Karrar, Maymona Abdelmagid, Manjola Balliu, Elena Nacca, Alessandro Atanasio, Ilaria Sestini, Audrey Désilets, Giuseppe Gaetano Loscocco, Giada Rotunno, Lambert Busque, Ayalew Tefferi, Alessandro Maria Vannucchi

Blood (2024) 143 (13): 1310–1314.

https://doi.org/10.1182/blood.2023023428

Published: 2024

Includes: Supplemental data

Journal Articles

Multi-Hit TP53 Mutations in Myeloid Neoplasms: Prognostic Impact of Morphologic Subtype Designation and Variant Allele Frequency

Maymona Abdelmagid, Kaaren K. Reichard, Omer Karrar, Rong He, Patricia Greipp, Rhett Ketterling, Mithun V Shah, Devendra Hiwase, Attilio Orazi, Daniel A. Arber, Naseema Gangat, Ayalew Tefferi

Blood (2023) 142 (Supplement 1): 4214.

https://doi.org/10.1182/blood-2023-183010

Published: 2023

Journal Articles

Prognostic Significance and Clinical Correlations of Myeloid Mutations in Myelofibrosis Based on Their Functional Class

Valentina Boldrini, Paola Guglielmelli, Giada Rotunno, Chiara Maccari, Giacomo Coltro, Giuseppe Gaetano Loscocco, Francesco Mannelli, Naseema Gangat, Ayalew Tefferi, Alessandro M. Vannucchi

Blood (2023) 142 (Supplement 1): 4533.

https://doi.org/10.1182/blood-2023-189571

Published: 2023

Journal Articles

ASXL1 / TET2 Genotype-Based Risk Stratification Outperforms ASXL1 Mutational Impact and Is Independent of Mutant Variant Allele Fractions (VAF) in CMML

Clifford M Csizmar, Mark Gurney, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle E. Hammond, Terra L Lasho, Christy M Finke, Christopher Dean, Abhishek A Mangaonkar, Naseema Gangat, Ayalew Tefferi, Hassan Alkhateeb, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 4615.

https://doi.org/10.1182/blood-2023-187235

Published: 2023

Journal Articles

A Phase 1b Trial of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia

Naseema Gangat, James M. Foran, Anna B. Halpern, Raajit K. Rampal, Natasha Novikov, Akshay Buch, Olivia Pelletier, William Savage, Ayalew Tefferi

Blood (2023) 142 (Supplement 1): 4564.

https://doi.org/10.1182/blood-2023-174922

Published: 2023

Journal Articles

STAG2 and PHF6 : Comparison of 2 X-Linked Gene Mutations in Myeloid Neoplasms

Bahga Katamesh, Amrutha Mittapalli, Rong He, David Viswanatha, Dragan Jevremovic, Mehrdad Hefazi, Antoine Saliba, Abhishek A Mangaonkar, Kebede Begna, William J. Hogan, Naseema Gangat, Mrinal M. Patnaik, Mithun V Shah, Ayalew Tefferi, Mark R. Litzow, Hassan Alkhateeb, Aref Al-Kali

Blood (2023) 142 (Supplement 1): 4304.

https://doi.org/10.1182/blood-2023-178244

Published: 2023

Journal Articles

Chromothripsis Orchestrates Leukemic Transformation in Blast Phase MPN through Targetable Amplification of DYRK1A

Blood (2023) 142 (Supplement 1): 993.

https://doi.org/10.1182/blood-2023-178556

Published: 2023

Journal Articles

Prognostic Relevance of Truncating ASXL1 Mutations and ASXL1 -Integrated Molecular Models in Proliferative CMML

Clifford M Csizmar, Mark Gurney, Terra L Lasho, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle E. Hammond, Christy M Finke, Abhishek A Mangaonkar, Aref Al-Kali, Naseema Gangat, Ayalew Tefferi, Hassan Alkhateeb, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 3241.

https://doi.org/10.1182/blood-2023-186881

Published: 2023

Journal Articles

Sodium-Glucose Co-Transporter-2 Inhibitor Use in the Setting of Myeloproliferative Neoplasms: Impact on Hemoglobin/Hematocrit Levels and Thrombosis Risk

Naseema Gangat, Omer Karrar, Maymona Abdelmagid, Moazah Iftikhar, Kaaren K. Reichard, Natasha Szuber, Ayalew Tefferi

Blood (2023) 142 (Supplement 1): 1815.

https://doi.org/10.1182/blood-2023-179596

Published: 2023

Journal Articles

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

Blood (2023) 142 (Supplement 1): 3234.

https://doi.org/10.1182/blood-2023-185023

Published: 2023

Journal Articles

Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53 -Mutations Using an Independent International Cohort

Blood (2023) 142 (Supplement 1): 3243.

https://doi.org/10.1182/blood-2023-187860

Published: 2023

Journal Articles

ASXL1 Mutation and Leukocytosis Undermine Spleen Response to Pacritinib in Myelofibrosis

Maymona Abdelmagid, Jeanne Palmer, James M. Foran, Aref Al-Kali, Omer Karrar, Kaaren K. Reichard, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2023) 142 (Supplement 1): 3194.

https://doi.org/10.1182/blood-2023-180235

Published: 2023

Journal Articles

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

Blood (2023) 142 (Supplement 1): 4608.

https://doi.org/10.1182/blood-2023-187905

Published: 2023

Journal Articles

T-Cells Immune Cluster Analysis Using Cytof Identifies Unique Patient Subgroups with TP53 Mutation and Predicts Complete Remission (CR) in Patients with Acute Myeloid Leukemia (AML) Receiving Venetoclax Plus Hypomethylating Agent Therapy

Talha Badar, Keith Knutson, James M. Foran, Naseema Gangat, Kevin Pavelko, Scott H. Kaufmann, Mark R. Litzow, Hemant S. Murthy, Davitte Cogen, Margaret Ushman, Arini Arsana, Aref Al-Kali, Hassan Alkhateeb, Ayalew Tefferi, Mrinal M. Patnaik, Mithun V Shah

Blood (2023) 142 (Supplement 1): 1563.

https://doi.org/10.1182/blood-2023-185654

Published: 2023

Journal Articles

Venetoclax + Cladribine + Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax + Hypomethylating Agent

Nickolas Steinauer, Kristen McCullough, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Abhishek A Mangaonkar, Antoine Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun V Shah, Animesh D. Pardanani, Talha Badar, Hemant S. Murthy, James M. Foran, Cecilia Y. Arana Yi, Ayalew Tefferi, Naseema Gangat

Blood (2023) 142 (Supplement 1): 2853.

https://doi.org/10.1182/blood-2023-185185

Published: 2023

Journal Articles

Type 1/like Calr Mutation in Momelotinib-Treated Patients with Myelofibrosis Is the Most Prominent Predictor of Drug Survival and Longevity without Transplant

Ayalew Tefferi, Animesh D. Pardanani, Kebede Begna, Aref Al-Kali, William J. Hogan, Mark R. Litzow, Naseema Gangat

Blood (2023) 142 (Supplement 1): 4555.

https://doi.org/10.1182/blood-2023-178869

Published: 2023

Journal Articles

Calr Variant Allele Frequency in Essential Thrombocythemia: Molecular Associations and Impact on Disease Phenotype and Outcome

Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Lambert Busque, Omer Karrar, Maymona Abdelmagid, Manjola Balliu, Alessandro Atanasio, Ilaria Sestini, Audrey Desilets, Giuseppe Gaetano Loscocco, Giada Rotunno, Marie-Christine Meunier, Michael Harnois, Ayalew Tefferi, Alessandro Maria Vannucchi

Blood (2023) 142 (Supplement 1): 6328.

https://doi.org/10.1182/blood-2023-174076

Published: 2023

Journal Articles

Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Blood (2023) 142 (Supplement 1): 591.

https://doi.org/10.1182/blood-2023-178837

Published: 2023

Journal Articles

ELN 2022 Favorable Genetic Risk Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agent: Predictors of Response and Survival

Kristen McCullough, Omer Karrar, Moazah Iftikhar, Maymona Abdelmagid, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Abhishek A Mangaonkar, Antoine Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun V Shah, Mrinal M. Patnaik, Animesh D. Pardanani, Ayalew Tefferi, Naseema Gangat

Blood (2023) 142 (Supplement 1): 5925.

https://doi.org/10.1182/blood-2023-182326

Published: 2023

NARROW

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

CALR mutation burden in essential thrombocythemia and disease outcome

Multi-Hit TP53 Mutations in Myeloid Neoplasms: Prognostic Impact of Morphologic Subtype Designation and Variant Allele Frequency

Prognostic Significance and Clinical Correlations of Myeloid Mutations in Myelofibrosis Based on Their Functional Class

ASXL1 / TET2 Genotype-Based Risk Stratification Outperforms ASXL1 Mutational Impact and Is Independent of Mutant Variant Allele Fractions (VAF) in CMML

A Phase 1b Trial of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia

STAG2 and PHF6 : Comparison of 2 X-Linked Gene Mutations in Myeloid Neoplasms

Chromothripsis Orchestrates Leukemic Transformation in Blast Phase MPN through Targetable Amplification of DYRK1A

Prognostic Relevance of Truncating ASXL1 Mutations and ASXL1 -Integrated Molecular Models in Proliferative CMML

Sodium-Glucose Co-Transporter-2 Inhibitor Use in the Setting of Myeloproliferative Neoplasms: Impact on Hemoglobin/Hematocrit Levels and Thrombosis Risk

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53 -Mutations Using an Independent International Cohort

ASXL1 Mutation and Leukocytosis Undermine Spleen Response to Pacritinib in Myelofibrosis

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

T-Cells Immune Cluster Analysis Using Cytof Identifies Unique Patient Subgroups with TP53 Mutation and Predicts Complete Remission (CR) in Patients with Acute Myeloid Leukemia (AML) Receiving Venetoclax Plus Hypomethylating Agent Therapy

Venetoclax + Cladribine + Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax + Hypomethylating Agent

Type 1/like Calr Mutation in Momelotinib-Treated Patients with Myelofibrosis Is the Most Prominent Predictor of Drug Survival and Longevity without Transplant

Calr Variant Allele Frequency in Essential Thrombocythemia: Molecular Associations and Impact on Disease Phenotype and Outcome

Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

ELN 2022 Favorable Genetic Risk Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agent: Predictors of Response and Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only